Literature DB >> 25215604

Full-length TDP-43 forms toxic amyloid oligomers that are present in frontotemporal lobar dementia-TDP patients.

Yu-Sheng Fang1, Kuen-Jer Tsai2, Yu-Jen Chang3, Patricia Kao4, Rima Woods4, Pan-Hsien Kuo5, Cheng-Chun Wu2, Jhih-Ying Liao6, Shih-Chieh Chou7, Vinson Lin8, Lee-Way Jin4, Hanna S Yuan5, Irene H Cheng6, Pang-Hsien Tu9, Yun-Ru Chen1.   

Abstract

Proteinaceous inclusions are common hallmarks of many neurodegenerative diseases. TDP-43 proteinopathies, consisting of several neurodegenerative diseases, including frontotemporal lobar dementia (FTLD) and amyotrophic lateral sclerosis (ALS), are characterized by inclusion bodies formed by polyubiquitinated and hyperphosphorylated full-length and truncated TDP-43. The structural properties of TDP-43 aggregates and their relationship to pathogenesis are still ambiguous. Here we demonstrate that the recombinant full-length human TDP-43 forms structurally stable, spherical oligomers that share common epitopes with an anti-amyloid oligomer-specific antibody. The TDP-43 oligomers are stable, have exposed hydrophobic surfaces, exhibit reduced DNA binding capability and are neurotoxic in vitro and in vivo. Moreover, TDP-43 oligomers are capable of cross-seeding Alzheimer's amyloid-β to form amyloid oligomers, demonstrating interconvertibility between the amyloid species. Such oligomers are present in the forebrain of transgenic TDP-43 mice and FTLD-TDP patients. Our results suggest that aside from filamentous aggregates, TDP-43 oligomers may play a role in TDP-43 pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25215604     DOI: 10.1038/ncomms5824

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  65 in total

1.  Mechanistic Insights into Hsp104 Potentiation.

Authors:  Mariana P Torrente; Edward Chuang; Megan M Noll; Meredith E Jackrel; Michelle S Go; James Shorter
Journal:  J Biol Chem       Date:  2016-01-08       Impact factor: 5.157

2.  Number and Brightness Analysis: Visualization of Protein Oligomeric State in Living Cells.

Authors:  Ryosuke Fukushima; Johtaro Yamamoto; Masataka Kinjo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Biology and Pathobiology of TDP-43 and Emergent Therapeutic Strategies.

Authors:  Lin Guo; James Shorter
Journal:  Cold Spring Harb Perspect Med       Date:  2017-09-01       Impact factor: 6.915

4.  Chronic Traumatic Encephalopathy in Athletes Involved with High-impact Sports.

Authors:  Cyrus Safinia; Eric M Bershad; H Brent Clark; Karen SantaCruz; Naila Alakbarova; Jose I Suarez; Afshin A Divani
Journal:  J Vasc Interv Neurol       Date:  2016-10

Review 5.  Mechanisms of TDP-43 Proteinopathy Onset and Propagation.

Authors:  Han-Jou Chen; Jacqueline C Mitchell
Journal:  Int J Mol Sci       Date:  2021-06-02       Impact factor: 5.923

Review 6.  Linking RNA Dysfunction and Neurodegeneration in Amyotrophic Lateral Sclerosis.

Authors:  Sami J Barmada
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 7.  Amyloidogenesis of Tau protein.

Authors:  Bartosz Nizynski; Wojciech Dzwolak; Krzysztof Nieznanski
Journal:  Protein Sci       Date:  2017-09-13       Impact factor: 6.725

8.  Detection of TDP-43 oligomers in frontotemporal lobar degeneration-TDP.

Authors:  Patricia F Kao; Yun-Ru Chen; Xiao-Bo Liu; Charles DeCarli; William W Seeley; Lee-Way Jin
Journal:  Ann Neurol       Date:  2015-06-30       Impact factor: 10.422

Review 9.  Novel Sites of Neuroprotective Action of Dimebon (Latrepirdine).

Authors:  Aleksey Ustyugov; Elena Shevtsova; Sergey Bachurin
Journal:  Mol Neurobiol       Date:  2015-06-30       Impact factor: 5.590

Review 10.  Could Sirtuin Activities Modify ALS Onset and Progression?

Authors:  Bor Luen Tang
Journal:  Cell Mol Neurobiol       Date:  2016-12-10       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.